Holen Sie sich die Stockscreener-App
0.57
0.73%
-0.0042
Handel nachbörslich:
.58
0.01
+1.75%
Schlusskurs vom Vortag:
$0.5742
Offen:
$0.571
24-Stunden-Volumen:
146.50K
Relative Volume:
0.09
Marktkapitalisierung:
$26.09M
Einnahmen:
$16.77M
Nettoeinkommen (Verlust:
$-11.87M
KGV:
-1.202
EPS:
-0.4742
Netto-Cashflow:
$-5.90M
1W Leistung:
+2.32%
1M Leistung:
+28.81%
6M Leistung:
+50.00%
1J Leistung:
-48.18%
1-Tages-Spanne:
$0.56
$0.58
1-Wochen-Bereich:
$0.51
$0.58
52-Wochen-Spanne:
$0.30
$1.14
Immunoprecise Antibodies Ltd Stock (IPA) Company Profile
Firmenname
Immunoprecise Antibodies Ltd
Sektor
Branche
Telefon
-
Adresse
-
Vergleichen Sie IPA mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
IPA
Immunoprecise Antibodies Ltd
|
0.57 | 25.50M | 16.77M | -11.87M | -5.90M | -0.4742 |
|
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
|
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
|
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
|
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
|
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Immunoprecise Antibodies Ltd Stock (IPA) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2022-12-02 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-10-25 | Eingeleitet | The Benchmark Company | Buy |
Immunoprecise Antibodies Ltd Aktie (IPA) Neueste Nachrichten
ImmunoPrecise Antibodies (NASDAQ:IPA) Stock Rating Upgraded by Wall Street Zen - Defense World
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Eng - GuruFocus
ImmunoPrecise Antibodies Engages CORE IR to Enhance Investor Engagement Efforts - Yahoo Finance
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group's 2025 Virtual Tech Conference | IPA Stock News - GuruFocus
ImmunoPrecise Antibodies to Present at Maxim Group’s 2025 Virtual Tech Conference - TipRanks
AI Breakthrough: ImmunoPrecise CEO Reveals Next-Gen Biotherapeutics Strategy at Major Tech Conference - Stock Titan
ImmunoPrecise Antibodies (IPA) to Present at Maxim Group’s 2025 Virtual Tech Conference - Yahoo Finance
What's Going on With Apple Stock? - The Globe and Mail
ImmunoPrecise Antibodies (IPA) Showcases Breakthrough in Epitope Mapping | IPA Stock News - GuruFocus
ImmunoPrecise Antibodies’ LENSai Platform Revolutionizes Epitope Mapping - TipRanks
IPA's LENSai™ Platform Delivers X-Ray--Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed | IPA Stock News - GuruFocus
IPA’s LENSai™ Platform Delivers X-Ray–Level Epitope Mapping Insights in Hours, Matching Gold-Standard Methods with Greater Speed - Yahoo Finance
ImmunoPrecise Antibodies Ltd.'s (NASDAQ:IPA) Shares Leap 28% Yet They're Still Not Telling The Full Story - simplywall.st
How ImmunoPrecise Antibodies ($IPA) Uses AI to Transform Antibody-Based Drug Discovery - Podomatic
Views of Wall Street’s Leading Experts on ImmunoPrecise Antibodies Ltd - Sete News
ImmunoPrecise Antibodies (OTCMKTS:IPATF) Trading Down 7% – Should You Sell? - Defense World
What is going on with ImmunoPrecise Antibodies Ltd? Sentiment Analysis - uspostnews.com
Will ImmunoPrecise Antibodies (NASDAQ:IPA) Spend Its Cash Wisely? - simplywall.st
H.C. Wainwright sets $50 target for ImmunoPrecise stock - Investing.com Australia
H.C. Wainwright sets $50 target for ImmunoPrecise stock By Investing.com - Investing.com South Africa
ImmunoPrecise Antibodies’ (IPA) “Buy” Rating Reiterated at HC Wainwright - Defense World
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI- - GuruFocus
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSai™ with FDA's Shift to Non-Animal Testing Methods - 01net
ImmunoPrecise Antibodies Aligns with FDA’s Move to Non-Animal Testing - TipRanks
ImmunoPrecise Antibodies Highlights Alignment of Proprietary AI-Driven Platform LENSaitm with FDA's Shift to Non-Animal Testing Methods - Lelezard
AI Breakthrough: How IPA's LENSai Platform Leads FDA's Historic Shift from Animal Testing - Stock Titan
ImmunoPrecise Antibodies Partners with RIBOPRO to Enhance Antibody Discovery - TipRanks
HC Wainwright Has Positive Outlook of IPA FY2025 Earnings - Defense World
ImmunoPrecise Antibodies (IPA) Upgraded to Buy: What Does It Mean for the Stock? - Yahoo Finance
HC Wainwright Has Bearish Forecast for IPA FY2028 Earnings - Defense World
ImmunoPrecise Antibodies’ (IPA) “Speculative Buy” Rating Reaffirmed at Benchmark - Defense World
Benchmark maintains Speculative Buy on Immunoprecise stock By Investing.com - Investing.com Australia
Benchmark maintains Speculative Buy on Immunoprecise stock - Investing.com
ImmunoPrecise Antibodies Ltd. (NASDAQ:IPA) Q3 2025 Earnings Call Transcript - Insider Monkey
ImmunoPrecise Antibodies (NASDAQ:IPA) Price Target Lowered to $5.00 at HC Wainwright - Defense World
ImmunoPrecise Antibodies Earnings Call Highlights Growth - TipRanks
Immunoprecise stock target cut to $5 by H.C. Wainwright - Investing.com Australia
ImmunoPrecise Antibodies Ltd. (IPA) Reports Q3 Loss, Misses Revenue Estimates - MSN
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... By GuruFocus - Investing.com Canada
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlights: Strategic Partnerships and ... - Yahoo
ImmunoPrecise Antibodies Ltd (IPA) Q3 2025 Earnings Call Highlig - GuruFocus
ImmunoPrecise Antibodies Third Quarter 2025 Earnings: CA$0.66 loss per share (vs CA$0.11 loss in 3Q 2024) - Yahoo
ImmunoPrecise Antibodies Reports Q3 FY25 Financial Results - TipRanks
Finanzdaten der Immunoprecise Antibodies Ltd-Aktie (IPA)
Umsatz
Nettogewinn
Free Cashflow
ENV
1.89%
3.74%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):